South Easton, Massachusetts–(Newsfile Corp. – June 12, 2020) – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, was the recent subject of an article by leading publisher Small Caps Daily, concerning their latest announcement of a $3.5 million order for hand sanitizers amid the ongoing global COVID-19 pandemic.
Recently, PBIO merged with CannawoRx, a company which has a strong and diversified portfolio of U.S. hemp-derived CBD products and intellectual property developed by its founders, Dr. Bobby Ghalili and Dr Adrienne Denese, who are medical and product development experts. In addition, PBIO announced a simultaneous acquisition of Dr. Denese’s acclaimed SkinScience® brand, which is a profitable and highly renowned company within the cosmetics space. SkinScience has generated approximately $18 million in revenue in 2019 alone and over $500 million over the past 17 years. The brand has sold over 25 million units and has won many customer choice beauty awards over the years.
SkinScience, a prominent name in the cosmeceutical industry, sought to address an inadequately met need amid the acute shortage of hand sanitizer as reported by numerous retail outlets. The Company developed, manufactured and began distributing a premium, dermatologically-focused hand sanitizer, and secured a large initial order based on its loyal and global customer base.
To read the Small Caps Daily article, please click here: https://smallcapsdaily.com/pressure-bio-the-3-5-million-order-for-hand-sanitizers-could-really-increase-the-momentum-of-this-stock/
● The SkinScience hand sanitizer, was a proprietary formula developed by founder Dr. Adrienne Denese, MD., Ph.D, who is a skilled scientist, physician and a visionary in the skin care market. The formula is less harsh on human skin, focusing on the dermatologic benefits and utilizing a relatively low, alcohol content.
● The $3.5 Million order of hand sanitizer, is a four month-supply, for just one customer; this large initial order, coupled with the increased demand for hand sanitizers as the world navigates through the pandemic and beyond, denotes an impressive forecast for 2020.
● The global hand sanitizer market is estimated at $5.5 billion and is expected to grow at an annualized rate of 22.7% over the next 5 years. The US continues to be the largest market for hand sanitizers and the demand for these products has increased during each of the public health epidemics since the SARS outbreak in 2003, H5N1 Avian influenza in 2006, and the 2009 outbreak of swine flu.
● PBIO benefits from the $3.5 Million order, through its acquisition of SkinScience. The entity resulting from the merger of CannawoRx and SkinScience will be known as Availa Bio and is will operate as a conglomerate, owning 31 patents and catering to multiple and varied markets such as pressure-based instruments, biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and many more.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.